|
시장보고서
상품코드
2024192
올리고뉴클레오티드 합성 시장(제4판) : 올리고 길이별, 용도별, 카테고리별, 유형별, 제품별, 지역별 예측, 인공지능(AI)의 영향 - 경영진용 가이드 및 컨설턴트용 가이드 포함(2026-2030년)Oligonucleotide Synthesis Markets 4th Edition. Forecasts by Oligo Length, Application, Category, Type, Product, and Region. With Executive and Consultant Guides. 2026 to 2030. Includes Impact of Artificial Intelligence. |
||||||
시장 개요:
합성 올리고뉴클레오티드의 합성이란 연구, 진단 및 치료 용도로 설계된 DNA 또는 RNA의 짧은 사슬을 화학적 또는 효소적으로 생성하는 것을 말합니다. 올리고뉴클레오티드는 일반적으로 약 15-200개 정도의 염기쌍으로 구성되어 있지만, 더 긴 구조의 경우 추가적인 분자생물학적 방법을 사용하여 조립할 수 있습니다. 이러한 합성 핵산 분자는 현대 유전체학, 분자진단, 유전자 편집 및 핵산 기반 치료제에 필수적인 역할을 하고 있습니다.
분자생물학, 유전체 의학, 생명공학의 발전과 함께 맞춤형 DNA 및 RNA 서열에 대한 수요가 증가함에 따라 세계 합성 올리고뉴클레오티드 합성 시장은 강력한 성장세를 보이고 있습니다. 2025년 시장 규모는 36억 8,000만 달러에 달할 것입니다. 시장은 14.8%의 속도로 성장하고 있으며, 2030년에는 73억 5,000만 달러에 달할 것으로 예상됩니다.
이러한 성장은 중합효소 연쇄 반응(PCR), 차세대 염기서열분석(NGS), 크리스퍼(CRISPR)와 같은 유전자 편집 기술, 안티센스 치료제, RNA 간섭(RNAi), 메신저 RNA(mRNA) 기술, 그리고 합성생물학 연구에서의 응용 분야 확대에 의해 주도되고 있습니다. 또한, 정밀의학(Precision Medicine) 접근법의 채택 확대도 맞춤형 올리고뉴클레오티드 합성 서비스에 대한 수요를 뒷받침하고 있습니다.
분자생물학 및 유전체학에서의 역할
합성 올리고뉴클레오티드는 분자생물학 워크플로우의 기본 도구입니다. PCR 프라이머와 프로브는 특정 유전자 영역에 결합하도록 설계된 짧은 DNA 서열에 의존하여 표적 서열의 증폭과 검출을 가능하게 합니다. 올리고뉴클레오티드는 시퀀싱 라이브러리 준비 워크플로우, 하이브리다이제이션 분석, 유전자 발현 분석에도 사용됩니다.
차세대 시퀀싱 기술의 발전으로 시퀀싱 어댑터, 인덱스 프라이머, 캡쳐 프로브에 사용되는 맞춤형 올리고뉴클레오티드에 대한 수요가 크게 증가하고 있습니다. 하이스루풋 시퀀싱 워크플로우에서는 많은 수의 고유한 올리고뉴클레오티드 서열이 필요한 경우가 많기 때문에 시장의 지속적인 확장을 촉진하고 있습니다.
CRISPR-Cas 시스템과 같은 유전자 편집 기술도 유전체 변형 활성을 유도하는 가이드 RNA를 생성하기 위해 합성 올리고뉴클레오티드에 의존하고 있습니다. 연구 개발 및 치료제 개발에서 유전자 편집 도구의 사용이 증가함에 따라 고품질 합성 핵산에 대한 수요가 더욱 증가하고 있습니다.
합성 올리고뉴클레오티드는 생물학적 회로나 변형 미생물을 구축하기 위해 DNA 서열을 설계하는 합성생물학에서도 매우 중요한 역할을 하고 있습니다.
치료 용도
합성 올리고뉴클레오티드 합성 시장에서 가장 빠르게 성장하고 있는 분야 중 하나는 핵산 기반 치료제입니다. 안티센스 올리고뉴클레오티드(ASO), 작은 간섭 RNA(siRNA), 마이크로 RNA 기반 치료제, 메신저 RNA(mRNA) 치료제는 유전자 발현 경로를 표적으로 하는 중요한 치료법입니다.
RNA 기반 치료제는 유전자 수준에서 질병의 메커니즘을 표적으로 삼을 수 있기 때문에 많은 투자가 이루어지고 있습니다. 올리고뉴클레오티드 치료제는 희귀유전질환, 암, 심혈관질환, 신경질환을 대상으로 개발이 진행되고 있습니다.
안정성, 결합 친화성 및 약동학적 특성을 향상시키기 위해 인산염 결합, 록도누클레산(LNA), 펩타이드누클레산(PNA)과 같은 화학적 변형이 종종 치료용 올리고뉴클레오티드에 통합됩니다.
치료용 올리고뉴클레오티드의 생산은 고순도와 엄격한 품질 관리가 요구되어 전문 위탁개발생산기관(CDMO)에 대한 수요를 뒷받침하고 있습니다.
기술 플랫폼
합성 올리고뉴클레오티드의 합성은 전통적으로 성장 중인 DNA 또는 RNA 사슬에 뉴클레오티드를 순차적으로 첨가하는 포스포라미데이트 화학에 의존해 왔습니다. 자동 합성 장치를 통해 다수의 올리고뉴클레오티드 서열을 고정밀도로 생산할 수 있습니다.
염기서열의 정확성을 확보하고 합성 부산물을 제거하기 위해 고성능 액체 크로마토그래피(HPLC), 질량 분석법 등의 정제 기술이 사용됩니다.
기존의 화학적 합성법을 대체할 수 있는 새로운 효소에 의한 DNA 합성 기술이 개발되고 있습니다. 효소를 이용한 방법은 합성 속도, 환경 친화적, 그리고 더 긴 DNA 서열을 생성하는 데 있어 이점을 제공할 수 있습니다.
자동화 및 고처리량 합성 플랫폼은 맞춤형 올리고뉴클레오티드 주문의 효율성을 향상시키고 납기를 단축합니다.
합성 기술과 생물정보학 도구의 통합으로 맞춤형 시퀀스를 신속하게 설계하고 주문할 수 있습니다.
시장 촉진요인
합성 올리고뉴클레오티드 합성 시장의 성장에는 몇 가지 요인이 기여하고 있습니다.
유전체 연구 및 차세대 시퀀싱 응용 분야가 확대됨에 따라 맞춤형 DNA 시퀀싱에 대한 수요가 증가하고 있습니다.
핵산 기반 치료제의 성장으로 고품질 RNA 및 DNA 합성에 대한 수요가 증가하고 있습니다.
PCR 기반 분자진단의 사용 확대는 프라이머와 프로브에 대한 지속적인 수요를 뒷받침하고 있습니다.
유전자 편집 기술의 발전으로 가이드 RNA 합성에 대한 수요가 증가하고 있습니다.
합성생물학의 연구로 인해 인공 DNA 구조체의 활용이 확대되고 있습니다.
맞춤의료에 대한 투자 증가는 표적치료 접근법의 발전을 뒷받침하고 있습니다.
합성 워크플로우의 자동화를 통해 확장성을 높이고 염기당 비용을 절감할 수 있습니다.
시장 세분화
합성 올리고뉴클레오티드 합성 시장은 제품 유형, 용도, 최종사용자 및 지역별로 세분화할 수 있습니다.
제품 유형별로는 DNA 올리고뉴클레오티드가 가장 큰 비중을 차지하고 있으며, RNA 올리고뉴클레오티드, 치료용으로 사용되는 변형된 올리고뉴클레오티드가 그 뒤를 잇고 있습니다.
용도별로는 PCR, 시퀀싱, 유전자 편집 워크플로우 등 연구 용도가 수요의 대부분을 차지하고 있습니다. 치료용은 빠르게 성장하고 있는 분야입니다.
최종사용자에는 학술 연구기관, 생명공학 기업, 제약회사, 위탁 연구기관, 진단 검사 기관 등이 포함됩니다.
북미는 탄탄한 생명공학 연구 인프라와 제약 산업의 존재감으로 인해 가장 큰 지역 시장으로 자리매김하고 있습니다. 유전체 연구에 대한 투자가 증가함에 따라 유럽과 아시아태평양 시장도 확대되고 있습니다.
경쟁 상황
합성 올리고뉴클레오티드 합성 시장에는 주요 생명과학 기업, 전문 합성 공급업체, 위탁 생산 기관 등이 포함됩니다.
경쟁은 합성 정확도, 납기, 비용 효율성, 복잡한 변형에 대한 대응 능력에 따라 좌우됩니다.
업체들은 시퀀싱 툴, 합성 서비스, 정제 및 분석적 검증을 결합한 통합 솔루션을 점점 더 많이 제공하고 있습니다.
합성 공급업체와 제약회사와의 전략적 제휴는 일반적이며, 특히 RNA 기반 치료제 개발에 있어서는 더욱 두드러집니다.
합성화학 및 뉴클레오티드 변형에 관한 지적재산권은 경쟁 우위를 확보하는 데 중요한 역할을 하고 있습니다.
향후 전망
유전체 기술과 핵산 기반 치료제가 발전함에 따라 합성 올리고뉴클레오티드 시장은 계속 확대될 것으로 예상됩니다.
효소 합성 기술을 통해 생산 효율을 높이고 환경에 미치는 영향을 줄일 수 있습니다.
유전자 편집과 합성생물학의 발전으로 더 길고 복잡한 DNA 구조체에 대한 수요가 증가할 수 있습니다.
합성 워크플로우의 자동화를 통해 염기당 비용을 절감하고 확장성을 향상시킬 수 있습니다.
인공지능 도구를 시퀀스 설계에 통합하여 합성 핵산의 성능을 향상시킬 수 있습니다.
RNA 치료제 파이프라인의 확장으로 고품질 올리고뉴클레오티드 생산에 대한 수요가 증가할 것으로 예상됩니다.
전체적으로 합성 올리고뉴클레오티드 합성은 유전체 연구, 분자진단 및 정밀 의학에 필수적인 기반 기술입니다. 지속적인 기술 혁신과 치료 용도의 확대는 시장의 지속적인 성장을 뒷받침할 것으로 예상됩니다.
목차
제1장 시장 가이드
제2장 소개와 시장 정의
제3장 올리고뉴클레오티드 합성
제4장 업계 개요
제5장 시장 요인
제6장 올리고뉴클레오티드 합성의 최근 동향
제7장 주요 기업 개요
제8장 세계의 올리고뉴클레오티드 합성 시장 개요
제9장 길이별 세계 시장
제10장 용도별 세계 시장
제11장 제품별 세계 시장
제12장 카테고리별 세계 시장
제13장 유형별 세계 시장
제14장 부록
표목차
그림목차
KSM 26.05.19Market Overview:
Synthetic oligonucleotide synthesis refers to the chemical or enzymatic production of short strands of DNA or RNA designed for use in research, diagnostics, and therapeutic applications. Oligonucleotides typically consist of sequences ranging from approximately 15 to 200 nucleotides, although longer constructs may be assembled through additional molecular biology techniques. These synthetic nucleic acid molecules play essential roles in modern genomics, molecular diagnostics, gene editing, and nucleic-acid-based therapeutics.
The global Synthetic Oligonucleotide Synthesis market has experienced strong growth as advances in molecular biology, genomic medicine, and biotechnology have expanded demand for custom DNA and RNA sequences. The market size in 2025 is USD 3.68 billion. The market is growing at 14.8%. The market will reach USD 7.35 billion in 2030.
Growth is being driven by expanding applications in polymerase chain reaction (PCR), next-generation sequencing (NGS), gene editing technologies such as CRISPR, antisense therapeutics, RNA interference (RNAi), messenger RNA (mRNA) technologies, and synthetic biology research. Increasing adoption of precision medicine approaches is also supporting demand for custom oligonucleotide synthesis services.
Role in Molecular Biology and Genomics
Synthetic oligonucleotides are fundamental tools in molecular biology workflows. PCR primers and probes rely on short DNA sequences designed to bind specific genetic regions, enabling amplification and detection of target sequences. Oligonucleotides are also used in sequencing library preparation workflows, hybridization assays, and gene expression analysis.
Advances in next-generation sequencing technologies have significantly increased demand for custom oligonucleotides used in sequencing adapters, indexing primers, and capture probes. High-throughput sequencing workflows often require large numbers of unique oligonucleotide sequences, supporting continued market expansion.
Gene editing technologies such as CRISPR-Cas systems also rely on synthetic oligonucleotides to create guide RNAs that direct genome modification activity. Increasing use of gene editing tools in research and therapeutic development is creating additional demand for high-quality synthetic nucleic acids.
Synthetic oligonucleotides also play a critical role in synthetic biology, where DNA sequences are designed to construct biological circuits or engineered microorganisms.
Therapeutic Applications
One of the fastest-growing segments of the synthetic oligonucleotide synthesis market is nucleic-acid-based therapeutics. Antisense oligonucleotides (ASOs), small interfering RNA (siRNA), microRNA-based therapies, and messenger RNA (mRNA) therapeutics represent important therapeutic modalities targeting gene expression pathways.
RNA-based therapeutics have attracted significant investment due to their ability to target disease mechanisms at the genetic level. Oligonucleotide therapies are being developed for rare genetic disorders, cancer, cardiovascular disease, and neurological conditions.
Chemical modifications such as phosphorothioate linkages, locked nucleic acids (LNAs), and peptide nucleic acids (PNAs) are often incorporated into therapeutic oligonucleotides to improve stability, binding affinity, and pharmacokinetic properties.
Manufacturing therapeutic oligonucleotides requires high purity and stringent quality control, supporting demand for specialized contract development and manufacturing organizations (CDMOs).
Technology Platforms
Synthetic oligonucleotide synthesis traditionally relies on phosphoramidite chemistry, which involves sequential addition of nucleotides to a growing DNA or RNA chain. Automated synthesizers enable production of large numbers of oligonucleotide sequences with high precision.
Purification techniques such as high-performance liquid chromatography (HPLC) and mass spectrometry are used to ensure sequence accuracy and remove synthesis byproducts.
Emerging enzymatic DNA synthesis technologies are being developed as alternatives to traditional chemical synthesis methods. Enzymatic approaches may offer advantages in synthesis speed, environmental sustainability, and production of longer DNA sequences.
Automation and high-throughput synthesis platforms are improving efficiency and reducing turnaround time for custom oligonucleotide orders.
Integration of synthesis technologies with bioinformatics tools enables rapid design and ordering of custom sequences.
Market Drivers
Several factors are contributing to growth of the synthetic oligonucleotide synthesis market.
Expansion of genomics research and next-generation sequencing applications is increasing demand for custom DNA sequences.
Growth in nucleic-acid-based therapeutics is creating demand for high-quality RNA and DNA synthesis.
Increasing use of PCR-based molecular diagnostics is supporting recurring demand for primers and probes.
Advances in gene editing technologies are increasing demand for guide RNA synthesis.
Synthetic biology research is expanding use of engineered DNA constructs.
Increasing investment in personalized medicine is supporting development of targeted therapeutic approaches.
Automation of synthesis workflows is improving scalability and reducing cost per base.
Market Segmentation
The synthetic oligonucleotide synthesis market can be segmented by product type, application, end user, and geographic region.
By product type, DNA oligonucleotides represent the largest segment, followed by RNA oligonucleotides and modified oligonucleotides used in therapeutic applications.
By application, research applications represent a significant portion of demand, including PCR, sequencing, and gene editing workflows. Therapeutic applications represent a rapidly growing segment.
End users include academic research institutions, biotechnology companies, pharmaceutical companies, contract research organizations, and diagnostic laboratories.
North America represents the largest regional market due to strong biotechnology research infrastructure and pharmaceutical industry presence. Europe and Asia-Pacific markets are also expanding as investment in genomics research increases.
Competitive Landscape
The synthetic oligonucleotide synthesis market includes large life sciences companies, specialized synthesis providers, and contract manufacturing organizations.
Competition is driven by synthesis accuracy, turnaround time, cost efficiency, and ability to support complex modifications.
Companies are increasingly offering integrated solutions combining sequence design tools, synthesis services, purification, and analytical validation.
Strategic partnerships between synthesis providers and pharmaceutical companies are common, particularly in development of RNA-based therapeutics.
Intellectual property related to synthesis chemistry and nucleotide modifications plays an important role in competitive positioning.
Future Outlook
The synthetic oligonucleotide synthesis market is expected to continue expanding as genomic technologies and nucleic-acid-based therapeutics advance.
Enzymatic synthesis technologies may improve production efficiency and reduce environmental impact.
Advances in gene editing and synthetic biology may increase demand for longer and more complex DNA constructs.
Automation of synthesis workflows may reduce cost per base and increase scalability.
Integration of artificial intelligence tools into sequence design may improve performance of synthetic nucleic acids.
Expansion of RNA therapeutics pipelines is expected to drive demand for high-quality oligonucleotide manufacturing.
Overall, synthetic oligonucleotide synthesis represents a critical enabling technology for genomics research, molecular diagnostics, and precision medicine. Continued technological innovation and expanding therapeutic applications are expected to support sustained market growth.
Table of Contents
1 Market Guides
- 1.1 Situation Analysis
- 1.1.1 Strategic Role in Modern Biotechnology
- 1.1.2 Manufacturing Complexity and Scale-Up Challenges
- 1.1.3 Supply Chain Constraints and Capacity Expansion
- 1.1.4 Regulatory Complexity for Therapeutic Applications
- 1.1.5 Pricing Pressure and Cost Structure Challenges
- 1.1.6 Technology Innovation and Competitive Differentiation
- 1.1.7 Dependence on Genomics and Therapeutics Markets
- 1.1.8 Intellectual Property and Competitive Landscape
- 1.1.9 Geographic Market Dynamics
- 1.1.10 Outlook and Strategic Implications
- 1.2 Guide for Executives and Marketing Staff
- 1.3 Guide for Investment Analysts and Management Consultants
- 1.4 Impact of Artificial Intelligence
2 Introduction and Market Definition
- 2.1 What is Oligonucleotide Synthesis?
- 2.1.1 The Enzyme Race
- 2.1.2 Data Storage - The Elephant in the Room
- 2.2 Market Definition
- 2.2.1 Market Size
- 2.2.2 Currency
- 2.2.3 Years
- 2.3 Methodology
- 2.3.1 Methodology
- 2.3.2 Sources
- 2.3.3 Authors
- 2.4 Perspective: Healthcare and the IVD Industry
- 2.4.1 Global Healthcare Spending
- 2.4.2 Spending on Diagnostics
- 2.4.3 Important Role of Insurance for Diagnostics
3 Oligonucleotide Synthesis
- 3.1 Synthesis Technology
- 3.2 Automation
- 3.3 Types of Oligonucleotides
- 3.4 PCR Primers
- 3.5 PCR Assays and Panels
- 3.6 Sequencing
- 3.7 DNA Microarrays
- 3.8 Fluorescence In Situ Hybridization (FISH)
- 3.9 Antisense Oligonucleotides
- 3.10 Other Uses of Oligonucleotides
- 3.11 Relationship to CRISPR and Gene Editing
4 Industry Overview
- 4.1 Players in a Dynamic Market
- 4.1.1 Academic Research Lab
- 4.1.2 Diagnostic Test Developer
- 4.1.3 Instrumentation Supplier
- 4.1.4 Chemical/Reagent Supplier
- 4.1.5 Pathology Supplier
- 4.1.6 Independent Clinical Laboratory
- 4.1.7 Public National/regional Laboratory
- 4.1.8 Hospital Laboratory
- 4.1.9 Physicians Office Lab (POLS)
- 4.1.10 Audit Body
- 4.1.11 Certification Body
5 Market Factors
- 5.1 Factors Driving Growth
- 5.1.1 The Role of Diagnostics and the Covid Effect
- 5.1.2 The RNA Based Vaccine
- 5.1.3 Genomic Blizzard
- 5.1.4 Antisense Revival
- 5.1.5 New Applications
- 5.2 Factors Limiting Growth
- 5.2.1 Declining Price
- 5.2.2 Technology Lag
- 5.2.3 COVID Realignment
- 5.3 The Next Five Years
6 Oligonucleotide Synthesis Recent Developments
- 6.1 Recent Developments - Importance and How to Use This Section
- 6.1.1 Importance of These Developments
- 6.1.2 How to Use This Section
- 6.2 Ono Pharmaceutical to acquire antisense oligonucleotide treatment
- 6.3 Codexis Enables Manufacturing of RNAi Therapeutics
- 6.4 Codexis Successfully Uses Enzymatic Synthesis
- 6.5 Oligo Factory Achieves GMP Compliance
- 6.6 Oligonucleotide Synthesis Scaled Up
- 6.7 Antisense Oligonucleotide Lowers Tau Tangles
- 6.8 Ansa Biotechnologies Synthesizes Longest Oligo at 1005 Bases
- 6.9 Agilent will double oligonucleotide capacity
- 6.10 RNA Synthesis Technology Commercialized by EnPlusOne
- 6.11 Quick and Automated Printing of Custom Oligos
- 6.12 WuXi STA Opens Large-Scale Oligo Manufacturing Facility
- 6.13 Secarna Pharmaceuticals' and Evotec Achieve Programme Designation
- 6.14 Aligos Discontinues Development of its Antisense Oligonucleotide
- 6.15 Seegene Obtains CE Mark for Oligo Based SARS-CoV-2 Assay
- 6.16 Biofidelity to Launch Mutation Detection Assay
- 6.17 Oligonucleotide Therapeutics Society Holds Meeting
- 6.18 New Oligonucleotide Synthesis Chemistry
- 6.19 Antisense Oligonucleotides Cross Rodents' Blood-Brain Barrier
- 6.20 New Rapid Multiplexed PCR Assay Uses Oligo Probes
- 6.21 MIT Devises Oligo 'File System' for DNA Data Storage
- 6.22 Nuclera Acquires E Ink Digital Microfluidics Business
- 6.23 Twist Bioscience Hits Milestone for DNA Data Storage
- 6.24 Twist Bioscience, Vivlion Partner on RNA Libraries for CRISPR
- 6.25 DNA Script Launching Benchtop Synthesizer for 'DNA on Demand'
- 6.26 RNA Disease Dx to Develop PoC Covid Test
- 6.27 Evonetix and Analog Devices Develop GEN3 DNA Synthesis Platform
- 6.28 ATDBio Receives Grant for Cancer Diagnosis Project
- 6.29 Twist Bioscience Announces Therapeutic Ab
- 6.30 Drugmakers boost oligo capacity amid Covid-19
- 6.31 Aligos Therapeutics in Study of Oligo Candidate
- 6.32 DNA Script Raises $89M for SYNTAX Launch
- 6.33 Codexis & Molecular Assemblies Partner for DNA Synthesis
- 6.34 NuProbe Licenses Oligo Technology from Rice
- 6.35 Genome editing with Cas9-oligo conjugates
- 6.36 OliX Pharma and AM Chemicals Partner for RNA Synthesis Support
- 6.37 Twist Bio To End Trade Secrets Suit
- 6.38 DNA Script, partners get grant for data storage
- 6.39 Xi's STA unit opens oligonucleotide plant
7 Profiles of Key Companies
- 7.1 Abbott Laboratories
- 7.2 Agilent
- 7.3 Ajinomoto Bio-Pharma
- 7.4 Amyris
- 7.5 Ansa BioTechnologies
- 7.6 ATG:biosynthetics
- 7.7 ATUM
- 7.8 Azenta
- 7.9 Bayer
- 7.10 Beckman Coulter Diagnostics (Danaher)
- 7.11 Becton, Dickinson and Company
- 7.12 Biogen
- 7.13 Biolytic Lab Performance
- 7.14 Biomatik
- 7.15 bioMerieux Diagnostics
- 7.16 Bioneer Corporation
- 7.17 Bio-Rad Laboratories, Inc.
- 7.18 Biospring
- 7.19 Bio-Synthesis
- 7.20 Biotage
- 7.21 Blue Heron Biotechnology (Eurofins Genomic)
- 7.22 Camena Bioscience
- 7.23 Cepheid (Danaher)
- 7.24 Chemgenes
- 7.25 Codexis
- 7.26 Cytena
- 7.27 Diasorin S.p.A.
- 7.28 DNA Script
- 7.29 Enzo Biochem
- 7.30 Eurofins Scientific
- 7.31 Eurogentec (Kaneka)
- 7.32 Evonetix
- 7.33 FASMAC
- 7.34 GE Healthcare
- 7.35 Genomatica
- 7.36 Genscript Biotech
- 7.37 Glycogene Inc.
- 7.38 Hologic
- 7.39 Hongene Biotech
- 7.40 Innovassynth
- 7.41 Integrated DNA Technologies (Danaher)
- 7.42 Ionis Pharmaceuticals
- 7.43 J&J Innovative Medicine
- 7.44 Kern Systems
- 7.45 LGC Biosearch Technologies
- 7.46 Macrogen
- 7.47 Maravai LifeSciences Holdings
- 7.48 Merck & Co., Inc
- 7.49 Microsynth
- 7.50 Millipore Sigma
- 7.51 Molecular Assemblies
- 7.52 New England Biolabs, Inc.
- 7.53 Nippon Shinyaku
- 7.54 Nitto Denko (Avecia)
- 7.55 Nuclera
- 7.56 Oligo Factory
- 7.57 Panagene
- 7.58 Primerdesign (Novacyt)
- 7.59 Qiagen
- 7.60 Revvity
- 7.61 Roche Diagnostics
- 7.62 Seegene
- 7.63 Siemens Healthineers
- 7.64 Synthego
- 7.65 TAG Copenhagen A/S
- 7.66 Thermo Fisher Scientific
- 7.67 Twist Bioscience
8 Oligonucleotide Synthesis Global Market Overview
- 8.1 Global Market Overview by Country
- 8.1.1 Table - Global Market by Country
- 8.1.2 Chart - Global Market by Country
- 8.2 Global Market Size by Length - Overview
- 8.2.1 Table - Global Market by Length
- 8.2.2 Chart - Global Market by Length - Base/Final Year Comparison
- 8.2.3 Chart - Global Market by Length - Base Year
- 8.2.4 Chart - Global Market by Length - Final Year
- 8.2.5 Chart - Global Market by Length - Share by Year
- 8.2.6 Chart - Global Market by Length - Segment Growth
- 8.3 Global Market Size by Application - Overview
- 8.3.1 Table - Global Market by Application
- 8.3.2 Chart - Global Market by Application - Base/Final Year Comparison
- 8.3.3 Chart - Global Market by Application - Base Year
- 8.3.4 Chart - Global Market by Application - Final Year
- 8.3.5 Chart - Global Market by Application - Share by Year
- 8.3.6 Chart - Global Market by Application - Segment Growth
- 8.4 Global Market Size by Product - Overview
- 8.4.1 Table - Global Market by Product
- 8.4.2 Chart - Global Market by Product - Base/Final Year Comparison
- 8.4.3 Chart - Global Market by Product - Base Year
- 8.4.4 Chart - Global Market by Product - Final Year
- 8.4.5 Chart - Global Market by Product - Share by Year
- 8.4.6 Chart - Global Market by Product - Segment Growth
- 8.5 Global Market Size by Category - Overview
- 8.5.1 Table - Global Market by Category
- 8.5.2 Chart - Global Market by Category - Base/Final Year Comparison
- 8.5.3 Chart - Global Market by Category - Base Year
- 8.5.4 Chart - Global Market by Category - Final Year
- 8.5.5 Chart - Global Market by Category - Share by Year
- 8.5.6 Chart - Global Market by Category - Segment Growth
- 8.6 Global Market Size by Type - Overview
- 8.6.1 Table - Global Market by Type
- 8.6.2 Chart - Global Market by Type - Base/Final Year Comparison
- 8.6.3 Chart - Global Market by Type - Base Year
- 8.6.4 Chart - Global Market by Type - Final Year
- 8.6.5 Chart - Global Market by Type - Share by Year
- 8.6.6 Chart - Global Market by Type - Segment Growth
9 Global Market by Length
- 9.1 Less than 20 mer Market
- 9.1.1 Table - Less than 20 mer Market by Country
- 9.1.2 Chart - Less than 20 mer Market Segment Growth
- 9.2 21-50 mer Market
- 9.2.1 Table - 21-50 mer Market by Country
- 9.2.2 Chart - 21-50 mer Market Segment Growth
- 9.3 51-100 mer Market
- 9.3.1 Table - 51-100 mer Market by Country
- 9.3.2 Chart - 51-100 mer Market Segment Growth
- 9.4 Greater than 100 mer Market
- 9.4.1 Table - Greater than 100 mer Market by Country
- 9.4.2 Chart - Greater than 100 mer Market Segment Growth
10 Global Market by Application
- 10.1 Research Market
- 10.1.1 Table - Research Market by Country
- 10.1.2 Chart - Research Market Segment Growth
- 10.2 Diagnostics Market
- 10.2.1 Table - Diagnostics Market by Country
- 10.2.2 Chart - Diagnostics Market Segment Growth
- 10.3 Therapeutics Market
- 10.3.1 Table - Therapeutics Market by Country
- 10.3.2 Chart - Therapeutics Market Segment Growth
- 10.4 Data Market
- 10.4.1 Table - Data Market by Country
- 10.4.2 Chart - Data Market Segment Growth
11 Global Market by Product
- 11.1 Oligonucleotides Market
- 11.1.1 Table - Oligonucleotides Market by Country
- 11.1.2 Chart - Oligonucleotides Market Segment Growth
- 11.2 Instruments Market
- 11.2.1 Table - Instruments Market by Country
- 11.2.2 Chart - Instruments Market Segment Growth
- 11.3 Nucleosides Market
- 11.3.1 Table - Nucleosides Market by Country
- 11.3.2 Chart - Nucleosides Market Segment Growth
- 11.4 Other Reagents Market
- 11.4.1 Table - Other Reagents Market by Country
- 11.4.2 Chart - Other Reagents Market Segment Growth
12 Global Market by Category
- 12.1 Primer Market
- 12.1.1 Table - Primer Market by Country
- 12.1.2 Chart - Primer Market Segment Growth
- 12.2 Probe Market
- 12.2.1 Table - Probe Market by Country
- 12.2.2 Chart - Probe Market Segment Growth
- 12.3 DNA Market
- 12.3.1 Table - DNA Market by Country
- 12.3.2 Chart - DNA Market Segment Growth
- 12.4 RNA Market
- 12.4.1 Table - RNA Market by Country
- 12.4.2 Chart - RNA Market Segment Growth
- 12.5 Other Nucleic Acid Market
- 12.5.1 Table - Other Nucleic Acid Market by Country
- 12.5.2 Chart - Other Nucleic Acid Market Segment Growth
13 Global Market by Type
- 13.1 Standard Oligonucleotides Market
- 13.1.1 Table - Standard Oligonucleotides Market by Country
- 13.1.2 Chart - Standard Oligonucleotides Market Segment Growth
- 13.2 Custom Oligonucleotides Market
- 13.2.1 Table - Custom Oligonucleotides Market by Country
- 13.2.2 Chart - Custom Oligonucleotides Market Segment Growth
14 Appendices
- 14.1 Typical Oligo Synthesis Price Lists
- 14.2 Medicare Clinical Lab Fee Schedule
- 14.3 Drug Approvals by Molecule Type - A Seven Year View
- 14.4 Growth of Approved IVD Test Menu
- 14.5 Growth of Approved Average IVD Test Fee
- 14.6 Share of Pharma R&D by Country
Table of Tables
- Table 1 Companies Formed to Exploit Enzyme Synthesis
- Table 2 Market Players by Type
- Table 3 Five Factors Driving Growth
- Table 4 Three Factors Limiting Growth
- Table 5 Global Market by Country/Region
- Table 6 Global Market by Length
- Table 7 Global Market by Application
- Table 8 Global Market by Product
- Table 9 Global Market by Category
- Table 10 Global Market by Type
- Table 11 Less than20 mer Market by Country
- Table 12 21-50 mer Market by Country
- Table 13 51-100 mer Market by Country
- Table 14 Greater than 100 mer Market by Country
- Table 15 Research Market by Country
- Table 16 Diagnostics Market by Country
- Table 17 Therapeutics Market by Country
- Table 18 Data Market by Country
- Table 19 Oligonucleotides Market by Country
- Table 20 Instruments Market by Country
- Table 21 Nucleosides Market by Country
- Table 22 Other Reagents Market by Country
- Table 23 Primer Market by Country
- Table 24 Probe Market by Country
- Table 25 DNA Market by Country
- Table 26 RNA Market by Country
- Table 27 Other Nucleic Acid Market by Country
- Table 28 Standard Oligonucleotides Market by Country
- Table 29 Custom Oligonucleotides Market by Country
- Table 30 Clinical Lab Fee Schedule
Table of Figures
- Figure 1 Global Health Spending
- Figure 2 The Lab Test Pie
- Figure 3 Phosphoramidites Structure
- Figure 4 DNA/Oligonucleotide Synthetic Cycle
- Figure 5 The Road to Diagnostics
- Figure 6 Growth rates of Oligionucleotide Synthesis by Application
- Figure 7 Market Size by Country
- Figure 8 Global Market by Length - Base vs. Final Year
- Figure 9 Length Market Base Year
- Figure 10 Length Market Final Year
- Figure 11 Length Share by Year
- Figure 12 Length Segment Growth
- Figure 13 Global Market by Application - Base vs. Final Year
- Figure 14 Application Market Base Year
- Figure 15 Application Market Final Year
- Figure 16 Application Share by Year
- Figure 17 Application Segment Growth
- Figure 18 Global Market by Product - Base vs. Final Year
- Figure 19 Product Market Base Year
- Figure 20 Product Market Final Year
- Figure 21 Product Share by Year
- Figure 22 Product Segment Growth
- Figure 23 Global Market by Category - Base vs. Final Year
- Figure 24 Category Market Base Year
- Figure 25 Category Market Final Year
- Figure 26 Category Share by Year
- Figure 27 Category Segment Growth
- Figure 28 Global Market by Type - Base vs. Final Year
- Figure 29 Type Market Base Year
- Figure 30 Type Market Final Year
- Figure 31 Type Share by Year
- Figure 32 Type Segment Growth
- Figure 33 Chart - Less than20 mer Market Growth
- Figure 34 Chart 21-50 mer Market Growth
- Figure 35 Chart - 51-100 mer Market Growth
- Figure 36 Chart - Greater than 100 mer Market Growth
- Figure 37 Chart Research Market Growth
- Figure 38 Chart - Diagnostics Market Growth
- Figure 39 Chart - Therapeutics market Growth
- Figure 40 Chart - Data Market Growth
- Figure 41 Chart Oligonucleotides Market Growth
- Figure 42 Chart - Instruments Market Growth
- Figure 43 Chart - Nucleosides Market Growth
- Figure 44 Chart - Other Reagents Market Growth
- Figure 45 Chart Primer Market Growth
- Figure 46 Chart - Probe Market Growth
- Figure 47 Chart - DNA Market Growth
- Figure 48 Chart - RNA Market Growth
- Figure 49 Chart - Other Nucleic Acid Market Growth
- Figure 50 Chart Standard Oligonucleotides Market Growth
- Figure 51 Chart - Custom Oligonucleotides Market Growth
- Figure 52 Eurofins Price List
- Figure 53 Hokkaido System Science Co. Price List
- Figure 54 Biobasic Price List
- Figure 55 Seven Years of FDA Approvals
- Figure 56 IVD Test Menu Growth
- Figure 57 IVD Test Average Fees - A Ten Year View
- Figure 58 Share of Pharma R&D by Country
